Vivint Pharma’s Rs. 400 Crore Investment Boosts Genome Valley

Vivint Pharma Announces Rs. 400 Crore Investment in New Injectables Manufacturing Unit in Genome Valley

Hyderabad, Aug 7: In a major boost to Telangana’s life sciences sector, Vivint Pharma has announced plans to establish a state-of-the-art injectables manufacturing facility in Genome Valley, Hyderabad. This significant expansion involves an investment of Rs. 400 crore and is expected to create around 1,000 jobs.

Chief Minister A. Revanth Reddy and IT and Industries Minister Sridhar Babu, currently touring the United States to attract investments, held discussions with representatives of Vivint Pharma. Following these discussions, the Chief Minister made a key announcement regarding the investment.

Vivint Pharma, a globally renowned company, already operates a research and development center in Genome Valley. With an additional Rs. 70 crore investment, the company aims to expand its presence in the international market. The new manufacturing plant in Hyderabad will be Vivint Pharma’s first in India, situated on a 5.5-acre site in Genome Valley, which will also house a research and innovation center.

Expressing his delight, Chief Minister A. Revanth Reddy said, “We are pleased that Vivint Pharma has decided to invest in Genome Valley. The Telangana government is committed to encouraging new innovations in life sciences and will provide the necessary concessions and infrastructure to support this initiative.”

Minister Sridhar Babu emphasized that Telangana offers a favorable environment for industries, particularly in Genome Valley, which continues to attract pharmaceutical companies. He noted that the state’s industrial policies are drawing interest from new companies, and Vivint Pharma’s new manufacturing center will significantly contribute to the growth of the life sciences sector in Telangana.

Vivint Pharma specializes in producing high-quality injectables and medicines, primarily in the oncology and critical care sectors. The company aims to leverage advanced manufacturing capabilities to meet the growing global demand for pharmaceutical products, while also providing employment opportunities for experts in the field.